As of close of business last night, C4 Therapeutics Inc’s stock clocked out at $8.22, down -5.63% from its previous closing price of $8.71. In other words, the price has decreased by -$0.49 from its previous closing price. On the day, 1192635 shares were traded.
Ratios:
To gain a deeper understanding of CCCC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.34 and its Current Ratio is at 6.34. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On December 13, 2023, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $12.
Credit Suisse Upgraded its Underperform to Neutral on February 24, 2023, whereas the target price for the stock was revised from $12 to $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 563.90M and an Enterprise Value of 381.19M. For the stock, the TTM Price-to-Sale (P/S) ratio is 27.16 while its Price-to-Book (P/B) ratio in mrq is 2.02. Its current Enterprise Value per Revenue stands at 18.37 whereas that against EBITDA is -2.98.
Stock Price History:
Over the past 52 weeks, CCCC has reached a high of $11.88, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is 7.87, while the 200-Day Moving Average is calculated to be 4.15.
Shares Statistics:
It appears that CCCC traded 4.95M shares on average per day over the past three months and 3.17M shares per day over the past ten days. A total of 60.47M shares are outstanding, with a floating share count of 57.73M. Insiders hold about 15.85% of the company’s shares, while institutions hold 63.53% stake in the company. Shares short for CCCC as of Feb 29, 2024 were 2.97M with a Short Ratio of 0.60, compared to 3.35M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.32% and a Short% of Float of 6.13%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.6, while EPS last year was -$0.71. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.28 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$1.08 and -$2.52 for the fiscal current year, implying an average EPS of -$1.85. EPS for the following year is -$1.92, with 8 analysts recommending between -$0.81 and -$3.01.
